Cytosorbents Corporation

NasdaqCM:CTSO Stock Report

Market Cap: US$47.7m

Cytosorbents Past Earnings Performance

Past criteria checks 0/6

Cytosorbents's earnings have been declining at an average annual rate of -16.1%, while the Medical Equipment industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 8.9% per year.

Key information

-16.1%

Earnings growth rate

-7.0%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate8.9%
Return on equity-122.5%
Net Margin-78.4%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Mar 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Jan 06
Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Nov 10
Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Jul 13
Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

May 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Mar 08
We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

CytoSorbents secures $4.3M contract by U.S. Department of Defense

Oct 06

CytoSorbents stock rises on US DoD contract to develop device for universal plasma

Sep 09

We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Sep 02
We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

CytoSorbents gets reimbursement for CytoSorb in Turkey

Aug 23

CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system

Aug 17

Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M

Aug 02

We're Not Very Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Mar 03
We're Not Very Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate

Revenue & Expenses Breakdown
Beta

How Cytosorbents makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:CTSO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2336-293716
30 Sep 2337-233615
30 Jun 2336-263615
31 Mar 2335-313615
31 Dec 2235-333715
30 Sep 2236-413918
30 Jun 2238-363819
31 Mar 2241-294018
31 Dec 2143-253816
30 Sep 2144-163713
30 Jun 2145-103610
31 Mar 2143-9339
31 Dec 2041-8329
30 Sep 2036-112910
30 Jun 2032-172811
31 Mar 2028-182612
31 Dec 1925-192412
30 Sep 1924-212411
30 Jun 1923-172210
31 Mar 1923-19238
31 Dec 1823-17238
30 Sep 1821-15217
30 Jun 1819-14216
31 Mar 1817-10184
31 Dec 1715-9163
30 Sep 1714-11153
30 Jun 1712-10144
31 Mar 1711-11134
31 Dec 1610-12134
30 Sep 168-9104
30 Jun 167-10104
31 Mar 166-594
31 Dec 155-984
30 Sep 154-1784
30 Jun 154-1774
31 Mar 154-2173
31 Dec 144-1962
30 Sep 144-951
30 Jun 144-851
31 Mar 143-741
31 Dec 132-732
30 Sep 132-732
30 Jun 132-733

Quality Earnings: CTSO is currently unprofitable.

Growing Profit Margin: CTSO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CTSO is unprofitable, and losses have increased over the past 5 years at a rate of 16.1% per year.

Accelerating Growth: Unable to compare CTSO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CTSO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.3%).


Return on Equity

High ROE: CTSO has a negative Return on Equity (-122.48%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.